BRAF and neoplasm: Colorectal cancer patients with the BRAF mutation in their tumours show resistance to the Epidermal growth factor receptor (EGFR) inhibitor Cetuximab and their response to the BRAF inhibitor Vemurafenib is limited [5,6].